Alere, Inc. (NYSE:ALR)

CAPS Rating: 3 out of 5

The Company is a global developer, manufacturer and marketer of vitro diagnostic products for the over-the-counter pregnancy and fertility/ovulation test market and the professional rapid diagnostic test markets.

Results 1 - 20 of 30 : 1 2 Next »

Recs

0
Member Avatar gfischer13 (91.25) Submitted: 7/13/2013 3:16:41 PM : Outperform Start Price: $27.30 ALR Score: +20.13

Actovist Filing: Coppersmith Capital and Scopia Management. Coppersmith claims upside of 74% - 136%. ($ 43...$ 58)
http://finance.yahoo.com/news/coppersmith-capital-files-definitive-proxy-120000036.html
Let's see

Recs

0
Member Avatar yoshetty (74.28) Submitted: 5/16/2012 11:02:25 PM : Outperform Start Price: $18.28 ALR Score: +55.39

Negative income cash flow positive small cap

Recs

0
Member Avatar jsgant13 (99.25) Submitted: 11/15/2010 11:25:59 PM : Outperform Start Price: $29.19 ALR Score: -33.41

ValueAct new holding Q3 2010

Recs

0
Member Avatar franktejon (< 20) Submitted: 7/6/2010 8:58:14 AM : Outperform Start Price: $26.29 ALR Score: -43.43

strong buy

Recs

1
Member Avatar carfang (65.83) Submitted: 8/26/2009 2:22:36 PM : Outperform Start Price: $36.33 ALR Score: -82.73

Once they improve their debt - will be well positioned

Recs

0
Member Avatar 000127 (62.18) Submitted: 7/22/2009 8:10:26 AM : Outperform Start Price: $32.55 ALR Score: -86.79

had some problems in ireland.....will rebound strong

Recs

0
Member Avatar onegreeneyes29 (< 20) Submitted: 1/28/2009 4:08:32 PM : Underperform Start Price: $25.00 ALR Score: +76.65

A poor second place in Cardiovascular POC, with an inferior product that is being sold under cost to buy marketshare. I wouldn't put my money here when they are going against a powerhouse like Roche. They are losing marketshare in the small segments of the market--the only place they ever excelled. IMI is also bogged down by a lot of acquisition confusion and look at their debt.

Recs

1
Member Avatar knuckledragger83 (41.08) Submitted: 1/27/2009 11:05:37 PM : Outperform Start Price: $25.00 ALR Score: -75.97

Stock is so controversial but is a real company that has been forced to stop making acquisitions and focus on integration. CEO is pounding 25% EPS growth. Trades at less than 10x forward PE or 0.4x PEG. Great company in right market position. Now be warned, this has been favorite of short sellers but hard to see that focus if earnings stay strong. Like a $40+ price by end of 2009.

Recs

0
Member Avatar aheydar2 (< 20) Submitted: 9/17/2008 11:20:28 PM : Outperform Start Price: $27.77 ALR Score: -33.38

high potential player who invests yest and grow constantly

Recs

1
Member Avatar Darkwingsd (< 20) Submitted: 8/29/2008 4:55:25 PM : Outperform Start Price: $33.99 ALR Score: -42.26

I think this stock has potential, The company buys out other companies in its goal to become the household name for invitro diagnostics. They want to reach the largest market out there for medical devices, which is the consumer market. They want to have similar to what some companies have in glucose monitoring tests for consumers, to be let them take control of their own health, which is a good idea, bu tthey need to develop the products to do it. They currently have a few of they product in development in relation to monitoring cardiovasular health which is the #1 disease/health problem in the US. SO there is definitely a market out there. They also make pregnancy tests too, so they have a pretty steady revenue base, around 1 Billion. so they have cash and leverage at their disposal. I would put the target price for them around 60-65 within a couple of years.

Recs

0
Member Avatar Colli002 (73.75) Submitted: 6/18/2008 3:15:30 PM : Underperform Start Price: $32.40 ALR Score: +32.69

Looking pretty bad - think I'll enjoy the slide down!

Recs

0
Member Avatar Tri3 (< 20) Submitted: 6/4/2008 8:27:44 AM : Outperform Start Price: $35.23 ALR Score: -38.37

+

Recs

0
Member Avatar River2River (27.25) Submitted: 5/21/2008 12:03:48 PM : Outperform Start Price: $30.93 ALR Score: -20.80

They aquired a company I really liked (Matria Health Care) and for some reason they got crushed on the aquisition to the point where I think Matria even ended up being a take under. The two together should do well over the next year or so.

Recs

0
Member Avatar davet999 (< 20) Submitted: 5/10/2008 8:29:04 AM : Outperform Start Price: $32.75 ALR Score: -29.33

IMA has acquired some very strong IP in the emerging cardiac diagnostic markets.

Recs

2
Member Avatar CaptainTBone (38.90) Submitted: 5/10/2008 6:58:43 AM : Outperform Start Price: $32.75 ALR Score: -29.33

The negatives have already been factored in and tehn some. With the Matria acquisition complete, you will begin to see the benefits of lower expenses and higher margins. The average age of the American population is growing due to seniors living longer and I think we will soon see IMA reap the benefits.

Recs

0
Member Avatar boater9384 (53.91) Submitted: 4/2/2008 11:50:16 PM : Outperform Start Price: $29.39 ALR Score: -20.19

There is a lot that points to this going up. Just check the numbers, the growth, the R&D expenditures, the debt/asset ratio, everything.

Recs

0
Member Avatar BorninBrookville (< 20) Submitted: 3/25/2008 12:19:08 PM : Outperform Start Price: $25.79 ALR Score: -4.42

A steal at this price.

Recs

0
Member Avatar cpelbaz (55.29) Submitted: 3/24/2008 2:59:37 PM : Outperform Start Price: $26.85 ALR Score: -9.82

.........................

Recs

0
Member Avatar cashmohoney (< 20) Submitted: 3/13/2008 12:21:36 PM : Outperform Start Price: $28.39 ALR Score: -22.59

innovative medical techniques way undervalued

Recs

8
Member Avatar Sangfarmer (< 20) Submitted: 2/28/2008 12:19:26 PM : Outperform Start Price: $28.59 ALR Score: -16.62

This firm has been unnecessarily punished as a "serial acquirer" that does not fully recognize its potential. As efficiencies are realized and new products are fully developed, this company will begin to see bottom line results which will reverse the negative image in the markets today. I believe this stock has reached a floor and will only go up from here. The only caveat would be a negative earnings surprise.

Results 1 - 20 of 30 : 1 2 Next »

Featured Broker Partners


Advertisement